Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade

por Wilkinson, Robert W., Leishman, Andrew J.
Publicado 2018

Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo

por Stewart, Ross, Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Smith, Paul D, Wilkinson, Robert W
Publicado 2014

Precise determination of toll-like receptor (TLR) 7 expression in multiple human tumor types

por Cumberbatch, Marie, Haughton, Nicola, Foster, Emily, Yap, Xiu Huan, Barry, Simon, Yamamoto, Setsuko, Murata, Masashi, Wilkinson, Robert W, Womack, Christopher
Publicado 2014

Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro

por Burke, Shannon, Shergold, Amy, Elder, Matthew J., Whitworth, Justine, Cheng, Xing, Jin, Hong, Wilkinson, Robert W., Harper, James, Carroll, Danielle K.
Publicado 2020

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments

por Sitnikova, Suzanne I., Walker, Jennifer A., Prickett, Laura B., Morrow, Michelle, Valge-Archer, Viia E., Robinson, Matthew J., Wilkinson, Robert W., Dovedi, Simon J.
Publicado 2023

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

por Luheshi, Nadia M., Coates-Ulrichsen, Jane, Harper, James, Mullins, Stefanie, Sulikowski, Michal G., Martin, Philip, Brown, Lee, Lewis, Arthur, Davies, Gareth, Morrow, Michelle, Wilkinson, Robert W.
Publicado 2016

A cell-engineered system to assess tumor cell sensitivity to CD8(+) T cell-mediated cytotoxicity

por Nelson, Nadine, Lopez-Pelaez, Marta, Palazon, Asis, Poon, Edmund, De La Roche, Maike, Barry, Simon, Valge-Archer, Viia, Wilkinson, Robert W., Dovedi, Simon J., Smith, Paul D.
Publicado 2019

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation

por Lopez-Pelaez, Marta, Young, Lucy, Vazquez-Chantada, Mercedes, Nelson, Nadine, Durant, Steve, Wilkinson, Robert W., Poon, Edmund, Gaspar, Miguel, Valge-Archer, Viia, Smith, Paul, Dovedi, Simon J.
Publicado 2022

MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue

por Ghadially, Hormas, Brown, Lee, Lloyd, Chris, Lewis, Leeanne, Lewis, Arthur, Dillon, Janette, Sainson, Richard, Jovanovic, Jelena, Tigue, Natalie J, Bannister, David, Bamber, Lisa, Valge-Archer, Viia, Wilkinson, Robert W
Publicado 2017

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade

por Dovedi, Simon, Adlard, Amy, Lipowska-Bhalla, Grazyna, McKenna, Conor, Jones, Sherrie, Cheadle, Eleanor, Stratford, Ian, Poon, Edmund, Morrow, Michelle, Stewart, Ross, Jones, Hazel, Wilkinson, Robert W, Honeychurch, Jamie, Illidge, Tim
Publicado 2014

Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple‐nega...

por Zanker, Damien J, Spurling, Alex J, Brockwell, Natasha K, Owen, Katie L, Zakhour, Jasmine M, Robinson, Tina, Duivenvoorden, Hendrika M, Hertzog, Paul J, Mullins, Stefanie R, Wilkinson, Robert W, Parker, Belinda S
Publicado 2020

A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models

por Adlard, Amy L, Dovedi, Simon J, Telfer, Brian A, Koga-Yamakawa, Erina, Pollard, Charlotte, Honeychurch, Jamie, Illidge, Timothy M, Murata, Masashi, Robinson, David T, Jewsbury, Philip J, Wilkinson, Robert W, Stratford, Ian J
Publicado 2014

Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma

por Egan, Donagh, Kreileder, Martina, Nabhan, Myriam, Iglesias-Martinez, Luis F., Dovedi, Simon J., Valge-Archer, Viia, Grover, Amit, Wilkinson, Robert W., Slidel, Timothy, Bendtsen, Claus, Barrett, Ian P., Brennan, Donal J., Kolch, Walter, Zhernovkov, Vadim
Publicado 2023

Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models

por Sitnikova, Suzanne Isabelle, Munnings-Tomes, Sophie, Galvani, Elena, Kentner, Stacy, Mulgrew, Kathy, Rands, Chris, España Agustí, Judit, Zhang, Tianhui, Ilieva, Kristina M, Rosignoli, Guglielmo, Ghadially, Hormas, Robinson, Matthew J, Slidel, Tim, Wilkinson, Robert W, Dovedi, Simon J
Publicado 2021

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

por Poon, Edmund, Mullins, Stefanie, Watkins, Amanda, Williams, Geoffrey S., Koopmann, Jens-Oliver, Di Genova, Gianfranco, Cumberbatch, Marie, Veldman-Jones, Margaret, Grosskurth, Shaun E., Sah, Vasu, Schuller, Alwin, Reimer, Corrine, Dovedi, Simon J., Smith, Paul D., Stewart, Ross, Wilkinson, Robert W.
Publicado 2017

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination...

por Dovedi, Simon J., Adlard, Amy L., Ota, Yosuke, Murata, Masashi, Sugaru, Eiji, Koga-Yamakawa, Erina, Eguchi, Ken, Hirose, Yuko, Yamamoto, Setsuko, Umehara, Hiroki, Honeychurch, Jamie, Cheadle, Eleanor J., Hughes, Gareth, Jewsbury, Philip J., Wilkinson, Robert W., Stratford, Ian J., Illidge, Timothy M.
Publicado 2016

Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

por Harper, James, Burke, Shannon, Travers, Jon, Rath, Nicola, Leinster, Andrew, Navarro, Christel, Franks, Ruth, Leyland, Rebecca, Mulgrew, Kathy, McGlinchey, Kelly, Brown, Lee, Dovedi, Simon J., Koopmann, Jens-Oliver, Durham, Nicholas M., Cheng, Xing, Jin, Hong, Eyles, Jim, Wilkinson, Robert W., Carroll, Danielle
Publicado 2021

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

por Mullins, Stefanie R., Vasilakos, John P., Deschler, Katharina, Grigsby, Iwen, Gillis, Pete, John, Julius, Elder, Matthew J., Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon J., Leishman, Andrew J., Luheshi, Nadia, Elvecrog, James, Tilahun, Ashenafi, Goodwin, Richard, Herbst, Ronald, Tomai, Mark A., Wilkinson, Robert W.
Publicado 2019

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

por Schofield, Darren J., Percival-Alwyn, Jennifer, Rytelewski, Mateusz, Hood, John, Rothstein, Raymond, Wetzel, Leslie, McGlinchey, Kelly, Adjei, Grace, Watkins, Amanda, Machiesky, LeeAnn, Chen, Weimin, Andrews, John, Groves, Maria, Morrow, Michelle, Stewart, Ross A., Leinster, Andrew, Wilkinson, Robert W., Hammond, Scott A., Luheshi, Nadia, Dobson, Claire, Oberst, Michael
Publicado 2021

Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation

por Chan, Denice T. Y., Jenkinson, Lesley, Haynes, Stuart W., Austin, Mark, Diamandakis, Agata, Burschowsky, Daniel, Seewooruthun, Chitra, Addyman, Alexandra, Fiedler, Sebastian, Ryman, Stephanie, Whitehouse, Jessica, Slater, Louise H., Gowans, Ellen, Shibata, Yoko, Barnard, Michelle, Wilkinson, Robert W., Vaughan, Tristan J., Holt, Sarah V., Cerundolo, Vincenzo, Carr, Mark D., Groves, Maria A. T.
Publicado 2020